New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 2, 2014
09:20 EDTAXL, SREV, RXII, OPEN, SQNM, RBS, NTRI, SQI, INVN, AVNR, MRK, CVX, BCOR, BIRT, IMMU, ISRG, ECYTOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Royal Bank of Scotland (RBS), up 9%... Sequenom (SQNM), up 8.2%... Nutrisystem (NTRI), up 11.5%... American Axle (AXL), up 2.9%. ALSO HIGHER: Wynn Resorts (WYNN), up 4% after earnings, shares upgraded at Sterne Agee... Avanir (AVNR), up 3.7% after upgraded at Mizuho... RXi Pharmaceuticals (RXII), up 27.4% after announcing results from study of RXI-109... Intuitive Surgical (ISRG), up 4% after announcing accelerated share repurchase. DOWN AFTER EARNINGS: Chevron (CVX), down 1%... OpenTable (OPEN), down 3.4%... Actuate (BIRT), down 18.2%... SciQuest (SQI), down 20%... ServiceSource (SREV), down 15.2%. ALSO LOWER: Endocyte (ECYT), down 60% after announcing DSMB recommends vintafolide PROCEED trial be stopped. The drug is being developed in partnership with Merck (MRK)... Immunomedics (IMMU), down 16% after filing to sell $30M worth of common stock in a spot secondary offering... InvenSense (INVN), down 9.3% after downgraded at Needham following the company's Q4 earnings report... Blucora (BCOR), down 10% after earnings, downgrade at Craig-Hallum.
News For CVX;RBS;ECYT;MRK;SQNM;ISRG;AVNR;OPEN;IMMU;INVN;RXII;BIRT;SQI;SREV;BCOR;NTRI;AXL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
July 22, 2015
07:04 EDTMRKMerck's Keytruda approved by EU for treatment of advanced melanoma in adults
Merck announced that the European Commission has approved KEYTRUDA, the company’s anti-PD-1 therapy, for the treatment of advanced melanoma in adults. The European Commission approval of pembrolizumab is based on data from three clinical studies conducted in more than 1,500 first-line and previously-treated patients with advanced melanoma. Pembrolizumab received European Commission regulatory approval based on Phase 3 data which showed it is the first and only anti-PD-1 therapy to provide a statistically superior survival benefit as a monotherapy compared to ipilimumab, the current standard of care for advanced melanoma. Today’s approval allows marketing of pembrolizumab in all 28 EU member states at the approved dose of 2 mg/kg every three weeks. The European Commission’s approval is based on data from three studies -- KEYNOTE-001, KEYNOTE-002 and KEYNOTE-006. These studies evaluated the efficacy and safety of pembrolizumab in advanced melanoma patients – across treatment lines, prognostic factors, tumor characteristics, and BRAF mutational status – and established 2 mg/kg every three weeks as the approved dose.
07:01 EDTISRGIntuitive Surgical price target raised to $675 from $616 at Jefferies
Jefferies raised its price target for Intuitive Surgical to $675 calling the company's Q2 results strong "across the board." Intuitive's upped guidance shows the positive trends are sustainability, the firm tells investors in a research note. It keeps a Buy rating on the name.
06:53 EDTISRGIntuitive Surgical upgraded to Buy from Hold at Canaccord
Subscribe for More Information
06:39 EDTCVXEuro, U.S. oil and gas groups to find tough competition in Iran, WSJ says
European and U.S. oil and gas firms drawn to Iran as sanctions lessen can expect not only opportunities, but also Iranian companies offering tough competition or joint ventures, the Wall Street Journal reports. Though no Iran-based companies have the clout of firms such as Exxon Mobil (XOM) or Schlumberger (SLB), companies that can take on engineering tasks are emerging and growing in Iran, the report says. If the Iran nuclear agreement comes into effect and sanctions are lifted against Iran sometime soon, those Iranian companies will be well positioned to compete for tens of billions of dollars worth of service contracts, the report adds. Other publicly traded companies in the space include BP (BP), Chevron (CVX), ConocoPhillips (COP), Royal Dutch Shell (RDS.A) and Total (TOT). Reference Link
06:05 EDTMRKMerck, Ablynx expand immuno-oncology collaboration
Subscribe for More Information
06:00 EDTISRGIntuitive Surgical price target raised to $625 from $575 at Barclays
Barclays analyst Matthew Taylor raised his price target for Intuitive Surgical to $625 saying the company's Q2 results should ease investor concerns around procedure growth and margins. The analyst calls the quarter "excellent" in a research note titled "Hitting All Cylinders." Taylor keeps an Overweight rating on the stock.
July 21, 2015
19:00 EDTISRGOn The Fly: After Hours Movers
Subscribe for More Information
16:59 EDTISRGIntuitive Surgical advances further to up over 12% in after-hours trading
16:58 EDTISRGIntuitive Surgical sees 2H15 gross profit margin 67%-68%
Subscribe for More Information
16:57 EDTISRGIntuitive Surgical raises 2015 procedural growth view to 11%-13% from 8%-11%
Comments from company's Q2 earnings conference call.
16:43 EDTISRGIntuitive Surgical advances almost 9% after reporting Q2 results
Subscribe for More Information
16:08 EDTISRGIntuitive Surgical Q2 worldwide da Vinci procedures grew 14%
Worldwide da Vinci procedures grew approximately 14% over the second quarter of 2014, up 8% sequentially over the first quarter of 2015, driven primarily by growth in U.S. general surgery procedures and broad-based procedure growth in Asia and other international markets. The Company shipped 118 da Vinci Surgical Systems, compared to 96 in the second quarter of 2014 and 99 in the first quarter of 2015.
16:07 EDTISRGIntuitive Surgical reports Q2 EPS $4.57, consensus $3.98
Subscribe for More Information
15:02 EDTISRGNotable companies reporting after market close
Subscribe for More Information
14:16 EDTISRGIntuitive Surgical July weekly 502.50 straddle priced for 6.4% movement into Q2
Subscribe for More Information
12:33 EDTISRGEarnings Watch: Intuitive Surgical down about 9% since last earnings
Subscribe for More Information
12:16 EDTISRGIntuitive Surgical technical comments before results
The stock has been trading in a sideways range from $480 at the low and $512 at the high since April of this year. Those two bounds may help us understand where price may go following earnings. If the news is bearish, a breakdown below $480 would resolve the range bearishly. Next supports to watch as potential downside objectives would be at $475, $470.79, and $467.45. If the news is a bullish surprise, the upper bound of the range at $512 would likely be tested. A breakout above $512 would resolve the range bullishly. Next resistance levels to watch as potential upside objectives would be at $525.57, $538.83, and $542.41.
08:30 EDTISRGIntuitive Surgical July weekly volatility elevated into Q2 and outlook
Subscribe for More Information
06:08 EDTRBSU.K. watchdog visited Barclays 186 times in 2014, Bloomberg reports
The FCA's supervisory team made 186 visits to Barclays (BCS) in 2014, more than any other British bank that year, Bloomberg reports. HSBC (HSBC) was next highest with 85 visits, with RBS (RBS) and Lloyds (LYG) following with 65 and 58 encounters, respectively, the report says. Reference Link
July 17, 2015
06:59 EDTISRGIntuitive Surgical Q2 expectations look reasonable, says Leerink
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use